Home > Publications Database > Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. > print

001     155560
005     20240320115511.0
024 7 _ |a pmc:PMC8545042
|2 pmc
024 7 _ |a 10.1177/0271678X211018904
|2 doi
024 7 _ |a pmid:34044665
|2 pmid
024 7 _ |a 0271-678X
|2 ISSN
024 7 _ |a 1559-7016
|2 ISSN
024 7 _ |a altmetric:106628142
|2 altmetric
037 _ _ |a DZNE-2021-00738
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Song, Mengmeng
|b 0
245 _ _ |a Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET.
260 _ _ |a London
|c 2021
|b Sage
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1643968175_17763
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The novel tau-PET tracer [18F]PI-2620 detects the 3/4-repeat-(R)-tauopathy Alzheimer's disease (AD) and the 4R-tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). We determined whether [18F]PI-2620 binding characteristics deriving from non-invasive reference tissue modelling differentiate 3/4R- and 4R-tauopathies. Ten patients with a 3/4R tauopathy (AD continuum) and 29 patients with a 4R tauopathy (CBS, PSP) were evaluated. [18F]PI-2620 PET scans were acquired 0-60 min p.i. and the distribution volume ratio (DVR) was calculated. [18F]PI-2620-positive clusters (DVR ≥ 2.5 SD vs. 11 healthy controls) were evaluated by non-invasive kinetic modelling. R1 (delivery), k2 & k2a (efflux), DVR, 30-60 min standardized-uptake-value-ratios (SUVR30-60) and the linear slope of post-perfusion phase SUVR (9-60 min p.i.) were compared between 3/4R- and 4R-tauopathies. Cortical clusters of 4R-tau cases indicated higher delivery (R1SRTM: 0.92 ± 0.21 vs. 0.83 ± 0.10, p = 0.0007), higher efflux (k2SRTM: 0.17/min ±0.21/min vs. 0.06/min ± 0.07/min, p < 0.0001), lower DVR (1.1 ± 0.1 vs. 1.4 ± 0.2, p < 0.0001), lower SUVR30-60 (1.3 ± 0.2 vs. 1.8 ± 0.3, p < 0.0001) and flatter slopes of the post-perfusion phase (slope9-60: 0.006/min ± 0.007/min vs. 0.016/min ± 0.008/min, p < 0.0001) when compared to 3/4R-tau cases. [18F]PI-2620 binding characteristics in cortical regions differentiate 3/4R- and 4R-tauopathies. Higher tracer clearance indicates less stable binding in 4R tauopathies when compared to 3/4R-tauopathies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a PI-2620
|2 Other
650 _ 7 |a Tau
|2 Other
650 _ 7 |a affinity
|2 Other
650 _ 7 |a binding
|2 Other
650 _ 7 |a kinetic modelling
|2 Other
650 _ 2 |a Fluorine Radioisotopes
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Image Interpretation, Computer-Assisted: methods
|2 MeSH
650 _ 2 |a Neuroimaging: methods
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Protein Isoforms: analysis
|2 MeSH
650 _ 2 |a Radiopharmaceuticals
|2 MeSH
650 _ 2 |a Tauopathies: diagnostic imaging
|2 MeSH
650 _ 2 |a tau Proteins: analysis
|2 MeSH
700 1 _ |a Beyer, Leonie
|b 1
700 1 _ |a Kaiser, Lena
|b 2
700 1 _ |a Barthel, Henryk
|b 3
700 1 _ |a Eimeren, Thilo
|0 P:(DE-2719)2812285
|b 4
|u dzne
700 1 _ |a Marek, Kenneth
|0 P:(DE-2719)9000201
|b 5
|u dzne
700 1 _ |a Nitschmann, Alexander
|b 6
700 1 _ |a Scheifele, Heinrich Maximilian
|0 P:(DE-2719)9001444
|b 7
|u dzne
700 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 8
|u dzne
700 1 _ |a Respondek, Gesine
|0 P:(DE-2719)2811600
|b 9
|u dzne
700 1 _ |a Kern, Maike
|b 10
700 1 _ |a Biechele, Gloria
|b 11
700 1 _ |a Hammes, Jochen
|b 12
700 1 _ |a Bischof, Gèrard
|b 13
700 1 _ |a Barbe, Michael
|b 14
700 1 _ |a Onur, Özgür
|b 15
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 16
|u dzne
700 1 _ |a Saur, Dorothee
|b 17
700 1 _ |a Schroeter, Matthias L
|b 18
700 1 _ |a Rumpf, Jost-Julian
|b 19
700 1 _ |a Rullmann, Michael
|b 20
700 1 _ |a Schildan, Andreas
|b 21
700 1 _ |a Patt, Marianne
|b 22
700 1 _ |a Neumaier, Bernd
|b 23
700 1 _ |a Barret, Olivier
|0 0000-0003-4247-184X
|b 24
700 1 _ |a Madonia, Jennifer
|b 25
700 1 _ |a Russell, David S
|0 0000-0002-9105-2943
|b 26
700 1 _ |a Stephens, Andrew W
|b 27
700 1 _ |a Mueller, Andre
|b 28
700 1 _ |a Roeber, Sigrun
|b 29
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 30
|u dzne
700 1 _ |a Bötzel, Kai
|b 31
700 1 _ |a Danek, Adrian
|0 P:(DE-2719)2810712
|b 32
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 33
|u dzne
700 1 _ |a Classen, Joseph
|b 34
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 35
|u dzne
700 1 _ |a Bartenstein, Peter
|b 36
700 1 _ |a Villemagne, Victor
|b 37
700 1 _ |a Drzezga, Alexander
|0 P:(DE-2719)2811239
|b 38
|u dzne
700 1 _ |a Seibyl, John
|b 39
700 1 _ |a Sabri, Osama
|0 P:(DE-2719)2814810
|b 40
|u dzne
700 1 _ |a Boening, Guido
|b 41
700 1 _ |a Ziegler, Sibylle
|b 42
700 1 _ |a Brendel, Matthias
|0 0000-0002-9247-2843
|b 43
773 _ _ |a 10.1177/0271678X211018904
|g p. 0271678X2110189 -
|0 PERI:(DE-600)2039456-1
|n 11
|p 2957-2972
|t Journal of cerebral blood flow & metabolism
|v 41
|y 2021
|x 1559-7016
856 4 _ |u https://journals.sagepub.com/doi/10.1177/0271678X211018904?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&
856 4 _ |u https://pub.dzne.de/record/155560/files/19577.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/155560/files/19577.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:155560
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812285
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)9000201
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9001444
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)9000852
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2811600
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2810441
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 32
|6 P:(DE-2719)2810712
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 35
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 38
|6 P:(DE-2719)2811239
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 40
|6 P:(DE-2719)2814810
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
913 0 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CEREBR BLOOD F MET : 2021
|d 2022-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J CEREBR BLOOD F MET : 2021
|d 2022-11-10
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2022-11-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-10
920 1 _ |0 I:(DE-2719)1111016
|k Clinical Dementia Research München
|l Clinical Dementia Research München
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Patient studies cologne
|x 1
920 1 _ |0 I:(DE-2719)1111015
|k AG Höglinger 2
|l Coordinator of Clinical Parkinson Research
|x 2
920 1 _ |0 I:(DE-2719)1011202
|k AG Boecker
|l Positron Emissions Tomography (PET)
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1011202
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21